Cetuximab conjugated vitamin E TPGS micelles for targeted delivery ofdocetaxel for treatment of triple negative breast cancers

Biomaterials

Volumn 34, Issue 38, 2013, Pages 10160-10171

  Kutty, Rajaletchumy Veloo ^a   Feng, Si Shen ^a,b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b Suzhou NanoStar Biopharm Inc Ltd   (China)

Author keywords

Biodegradable polymers; Cancer nanotechnology; Drug targeting; Molecular biomaterials; Nanomedicine; Pharmaceutical nanotechnology

Indexed keywords

BREAST CANCER CELLS; CANCER NANOTECHNOLOGY; DRUG ENCAPSULATION EFFICIENCY; DRUG-TARGETING; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROGESTERONE RECEPTOR; THERAPEUTIC EFFECTS; TRIPLE-NEGATIVE BREAST CANCERS;

BIODEGRADABLE POLYMERS; CELL CULTURE; DISEASES; DRUG PRODUCTS; MEDICAL NANOTECHNOLOGY; MICELLES; NANOTECHNOLOGY; SURFACE CHEMISTRY;

CELLS;

CETUXIMAB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TOCOFERSOLAN;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; CONFOCAL LASER MICROSCOPY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG PENETRATION; DRUG RELEASE; DRUG UPTAKE; FIBROBLAST; FLOW CYTOMETRY; IN VITRO STUDY; MICELLE; MOUSE; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITATIVE RESEARCH; QUANTITATIVE STUDY; SURFACE CHARGE; THERAPY EFFECT; TRIPLE NEGATIVE BREAST CANCER; ULTRAVIOLET SPECTROPHOTOMETRY; X RAY PHOTOELECTRON SPECTROSCOPY; ZETA POTENTIAL;

BIODEGRADABLE POLYMERS; CANCER NANOTECHNOLOGY; DRUG TARGETING; MOLECULAR BIOMATERIALS; NANOMEDICINE; PHARMACEUTICAL NANOTECHNOLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; HUMANS; MICE; MICELLES; NANOMEDICINE; NANOTECHNOLOGY; TAXOIDS; TRIPLE NEGATIVE BREAST NEOPLASMS; VITAMIN E;

EID: 84885382152     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.09.043     Document Type: Article

References (56)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013, 63(1):11-30.
2. Wong C., Chen S. The development, application and limitations of breast cancer cell lines to study tamoxifen and aromatase inhibitor resistance. JSteroid Biochem Mol Biol 2012, 131(3-5):83-92.
3. Goldhirsch A., Colleoni M., Gelber R.D. Endocrine therapy of breast cancer. Ann Oncol 2002, 13:61-68.
4. Raff J.P., Rajdev L., Malik U., Novik Y., Manalo J.M., Negassa A., et al. Phase II study of weekly docetaxel alone or in combination with trastuzumab in patients with metastatic breast cancer. Clin Breast Cancer 2004, 4(6):420-427.
5. Hudis C.A. Drug therapy: trastuzumab - mechanism of action and use in clinical practice. NEngl J Med 2007, 357(1):39-51.
6. Baselga J., Norton L., Albanell J., Kim Y.M., Mendelsohn J. Recombinant humanized anti-her2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against her2/neu overexpressing human breast cancer xenografts. Cancer Res 1999, 59(8):2020. [vol. 58, pg 2825, 1998].
7. Foulkes W.D., Smith I.E., Reis-Filho J.S. Triple-negative breast cancer. NEngl J Med 2010, 363(20):1938-1948.
8. Duffy M.J., McGowan P.M., Crown J. Targeted therapy for triple-negative breast cancer: where are we?. Int J Cancer 2012, 131(11):2471-2477.
9. Dent R., Trudeau M., Pritchard K.I., Hanna W.M., Kahn H.K., Sawka C.A., et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007, 13(15):4429-4434.
10. Amend K., Hicks D., Ambrosone C.B. Breast cancer in African-American women: differences in tumor biology from European-American women. Cancer Res 2006, 66(17):8827-8830.
11. Bauer K.R., Brown M., Cress R.D., Parise C.A., Caggiano V. Descriptive analysis of estrogen receptor (ER) negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype - a population-based study from the California cancer registry. Cancer 2007, 109(9):1721-1728.
12. Lehmann B.D., Bauer J.A., Chen X., Sanders M.E., Chakravarthy A.B., Shyr Y., et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. JClin Invest 2011, 121(7):2750-2767.
13. Rakha E.A., Ellis I.O. Triple-negative/basal-like breast cancer: review. Pathology 2009, 41(1):40-47.
14. Rakha E.A., El-Sayed M.E., Green A.R., Lee A.H., Robertson J.F., Ellis I.O. Prognostic markers in triple-negative breast cancer. Cancer 2007, 109(1):25-32.
15. Pal S.K., Childs B.H., Pegram M. Triple negative breast cancer: unmet medical needs. Breast Cancer Res Treat 2011, 125(3):627-636.
16. Kaplan H.G., Malmgren J.A., Atwood M. T1N0 triple negative breast cancer: risk of recurrence and adjuvant chemotherapy. Breast J 2009, 15(5):454-460.
17. Yagata H., Kajiura Y., Yamauchi H. Current strategy for triple-negative breast cancer: appropriate combination of surgery, radiation, and chemotherapy. Breast Cancer 2011, 18(3):165-173.
18. Nguyen P.L., Taghian A.G., Katz M.S., Niemierko A., Abi Raad R.F., Boon W.L., et al. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and her-2 is associated with local and distant recurrence after breast-conserving therapy. JClin Oncol 2008, 26(14):2373-2378.
19. Haffty B.G., Yang Q., Reiss M., Kearney T., Higgins S.A., Weidhaas J., et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. JClin Oncol 2006, 24(36):5652-5657.
20. Freedman G.M., Anderson P.R., Li T., Nicolaou N. Locoregional recurrence of triple-negative breast cancer after breast-conserving surgery and radiation. Cancer 2009, 115(5):946-951.
21. Kyndi M., Sorensen F.B., Knudsen H., Overgaard M., Nielsen H.M., Overgaard J. Estrogen receptor, progesterone receptor, her-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group. JClin Oncol 2008, 26(9):1419-1426.
22. Liedtke C., Mazouni C., Hess K.R., Andre F., Tordai A., Mejia J.A., et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. JClin Oncol 2008, 26(8):1275-1281.
23. Isakoff S.J. Triple-negative breast cancer role of specific chemotherapy agents. Cancer J 2010, 16(1):53-61.
24. Carey L.A., Dees E.C., Sawyer L., Gatti L., Moore D.T., Collichio F., et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007, 13(8):2329-2334.
25. Henderson I.C., Berry D.A., Demetri G.D., Cirrincione C.T., Goldstein L.J., Martino S., et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. JClin Oncol 2003, 21(6):976-983.
26. Gelmon K., Dent R., Mackey J.R., Laing K., McLeod D., Verma S. Targeting triple-negative breast cancer: optimising therapeutic outcomes. Ann Oncol 2012, 23(9):2223-2234.
27. Herbst R.S., Shin D.M. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors - a new paradigm for cancer therapy. Cancer 2002, 94(5):1593-1611.
28. Milenic D.E., Wong K.J., Baidoo K.E., Ray G.L., Garmestani K., Williams M., et al. Cetuximab: preclinical evaluation of a monoclonal antibody targeting EGFR for radioimmunodiagnostic and radioimmunotherapeutic applications. Cancer Biother Radiopharm 2008, 23(5):619-631.
29. Nielsen T.O., Hsu F.D., Jensen K., Cheang M., Karaca G., Hu Z.Y., et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004, 10(16):5367-5374.
30. Brabender J., Danenberg K.D., Metzger R., Schneider P.M., Park J.M., Salonga D., et al. Epidermal growth factor receptor and her2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin Cancer Res 2001, 7(7):1850-1855.
31. Oda K., Matsuoka Y., Funahashi A., Kitano H. Acomprehensive pathway map of epidermal growth factor receptor signaling. Mol Syst Biol 2005, 1. 2005.0010.
32. Livasy C.A., Karaca G., Nanda R., Tretiakova M.S., Olopade O.I., Moore D.T., et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 2006, 19(2):264-271.
33. Feng S.S. Nanomedicine: nanoparticles of biodegradable polymers for cancer diagnosis and treatment. COSMOS J Singapore Natl Acad Sci 2008, 4(2):185-201.
34. Feng S.S., Zhao L.Y., Zhang Z.P., Bhakta G., Win K.Y., Dong Y.C., et al. Chemotherapeutic engineering: vitamin E TPGS-emulsified nanoparticles of biodegradable polymers realized sustainable paclitaxel chemotherapy for 168h invivo. Chem Eng Sci 2007, 62(23):6641-6648.
35. Mi Y., Guo Y.J., Feng S.S. Nanomedicine for multimodality treatment of cancer. Nanomedicine (Lond) 2012, 7(12):1791-1794.
36. Chandrasekharan P., Maity D., Yong C.X., Chuang K.H., Ding J., Feng S.S. Vitamin E (D-alpha-tocopheryl-co-poly(ethylene glycol) 1000 succinate) micelles-superparamagnetic iron oxide nanoparticles for enhanced thermotherapy and MRI. Biomaterials 2011, 32(24):5663-5672.
37. Muthu M.S., Kulkarni S.A., Liu Y.T., Feng S.S. Development of docetaxel-loaded vitamin E TPGS micelles: formulation optimization, effects on brain cancer cells and biodistribution in rats. Nanomedicine (Lond) 2012, 7(3):353-364.
38. Mi Y., Liu Y., Feng S.S. Formulation of docetaxel by folic acid-conjugated d-alpha-tocopheryl polyethylene glycol succinate 2000 (vitamin E TPGS(2k)) micelles for targeted and synergistic chemotherapy. Biomaterials 2011, 32(16):4058-4066.
39. Mu L., Feng S.S. Vitamin E TPGS used as emulsifier in the solvent evaporation/extraction technique for fabrication of polymeric nanospheres for controlled release of paclitaxel (Taxol). JControl Release 2002, 80(1-3):129-144.
40. Graham J., Muhsin M., Kirkpatrick P. Cetuximab. Nat Rev Drug Discov 2004 Jul, 3(7):549-550.
41. Sunada H., Magun B.E., Mendelsohn J., Macleod C.L. Monoclonal-antibody against epidermal growth-factor receptor is internalized without stimulating receptor phosphorylation. Proc Natl Acad Sci U S A 1986, 83(11):3825-3829.
42. Fan Z., Lu Y., Wu X.P., Mendelsohn J. Antibody-induced epidermal growth-factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma-cells. JBiol Chem 1994, 269(44):27595-27602.
43. Petit A.M., Rak J., Hung M.C., Rockwell P., Goldstein N., Fendly B., et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells invitro and invivo - angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 1997, 151(6):1523-1530.
44. Zhang W., Gordon M., Schultheis A.M., Yang D.Y., Nagashima F., Azuma M., et al. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. JClin Oncol 2007, 25(24):3712-3718.
45. Baselga J. The EGFR as a target for anticancer therapy - focus on cetuximab. Eur J Cancer 2001, 37:S16-S22.
46. Zhao J., Mi Y., Feng S.S. Targeted co-delivery of docetaxel and siPlk1 by herceptin-conjugated vitamin E TPGS based immunomicelles. Biomaterials 2013, 34(13):3411-3421.
47. Sun B., Feng S.S. Trastuzumab-functionalized nanoparticles of biodegradable copolymers for targeted delivery of docetaxel. Nanomedicine (Lond) 2009, 4(4):431-445.
48. Zhao J., Mi Y., Liu Y.T., Feng S.S. Quantitative control of targeting effect of anticancer drugs formulated by ligand-conjugated nanoparticles of biodegradable copolymer blend. Biomaterials 2012, 33(6):1948-1958.
49. Liu Y., Li K., Liu B., Feng S.S. Astrategy for precision engineering of nanoparticles of biodegradable copolymers for quantitative control of targeted drug delivery. Biomaterials 2010, 31(35):9145-9155.
50. Shamsipour F., Zarnani A.H., Ghods R., Chamankhah M., Forouzesh F., Vafaei S., et al. Conjugation of monoclonal antibodies to super paramagnetic iron oxide nanoparticles for detection of her2/neu antigen on breast cancer cell lines. Avicenna J Med Biotechnol 2009, 1(1):27-31.
51. Blanco E., Kessinger C.W., Sumer B.D., Gao J. Multifunctional micellar nanomedicine for cancer therapy. Exp Biol Med 2009, 234(2):123-131.
52. Maeda H., Wu J., Sawa T., Matsumura Y., Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. JControl Release 2000, 65(1-2):271-284.
53. Mi Y., Zhao J., Feng S.S. Targeted co-delivery of docetaxel, cisplatin and herceptin by vitamin E TPGS-cisplatin prodrug nanoparticles for multimodality treatment of cancer. JControl Release 2013, 169(3):185-192.
54. Win K.Y., Feng S.S. Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials 2005, 26(15):2713-2722.
55. Bhattacharyya S., Bhattacharya R., Curley S., McNiven M.A., Mukherjee P. Nanoconjugation modulates the trafficking and mechanism of antibody induced receptor endocytosis. Proc Natl Acad Sci U S A 2010, 107(33):14541-14546.
56. De S., Cipriano R., Jackson M.W., Stark G.R. Overexpression of kinesins mediates docetaxel resistance in breast cancer cells. Cancer Res 2009, 69(20):8035-8042.